BrightPath Biotherapeutics Co., Ltd. 4594
ブライトパス・バイオ株式会社 · Biotechnology · Growth
Governance Compliance: TSE Status: Untracked
Similar ›
Fact Sheet (PDF)
BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan. The company is developing BP2201, a product candidate in Phase I clinical trials to target cancer antigens in various types of cancer; BP2202, Phase I clinical trial to target cancer; and BP2301, a product candidate in Phase I clinical trials for the treatment of solid tumors sarcoma and gynecological cancers. In addition, its product candidates in preclinical trials include BP1200 that targets CD73; BP1202 that targets CD39; BP1210, which suppresses T cell cytotoxicity; BP1212 to inhibit TIM-3 and CD39; BP1209 to target tumor-specific neoantigens; and BP1223 to target blood cancers. The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017. The company was incorporated in 2003 and is headquartered in Kawasaki, Japan.
Price
¥44
Market Cap
¥4.0B
Ent. Value
¥3.2B
Net Cash
¥810M
Shares Out.
90.5M
P / E
EV / EBIT
P / Book
4.41×
P / NCAV
4.55×
Div. Yield
⬇ Excel
Metric FY 2024
EDINET ↗
FY 2023
EDINET ↗
FY 2022
EDINET ↗
FY 2021
EDINET ↗
FY 2020
EDINET ↗
Net Sales ¥1M ¥0M ¥5M ¥15M ¥3M
Cost of Sales ¥0M ¥0M ¥2M ¥3M ¥1M
Gross Profit ¥1M ¥0M ¥3M ¥12M ¥1M
SG&A ¥1.2B ¥1.2B ¥1.5B ¥1.5B ¥1.7B
Operating Income ¥-1.2B ¥-1.2B ¥-1.5B ¥-1.5B ¥-1.7B
Non-Operating Income ¥17M ¥0M ¥1M ¥0M ¥3M
Interest Income ¥0M ¥0M ¥0M ¥0M ¥0M
Non-Operating Expenses ¥4M ¥4M ¥7M ¥6M ¥9M
Ordinary Income ¥-1.1B ¥-1.2B ¥-1.5B ¥-1.5B ¥-1.7B
Pre-tax Income ¥-1.1B ¥-1.2B ¥-1.5B ¥-1.5B ¥-1.7B
Income Taxes ¥2M ¥2M ¥2M ¥2M ¥2M
Current Tax ¥2M ¥2M ¥2M ¥2M ¥2M
Net Income (owners) ¥-1.2B ¥-1.2B ¥-1.5B ¥-1.5B ¥-1.7B
EBITDA ¥-1.2B ¥-1.5B ¥-1.4B ¥-1.7B
EPS ¥-14.12 ¥-18.21 ¥-24.90 ¥-28.55 ¥-36.14
Shares Outstanding 90.5M 70.7M 62.9M 55.3M 50.8M
Shares Issued (total) 90.5M 70.7M 62.9M 55.3M 50.8M